Nanobody CAR-T cells in cancer: From molecular design to clinical translation
CAR-T-клетки на основе нанотел в онкологии: от молекулярного конструирования до клинической трансляции
2025-11-29
SCID: 54.1/zhrrfvhj
Discuss with AI
BCMA targetingchimeric antigen receptorsnanobody CAR-T cellssingle-domain antibodies (VHHs)synthetic biology circuits
Figures from the paper
Abstract (AI)
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the management of hematologic malignancies. This review provides an overview of nanobody-based CAR-T therapy, highlighting how structural advancements in single-domain antibody (VHH) design enhance tumor targeting, safety, and manufacturability. Traditional CARs utilizing single-chain variable fragments (ScFv) continue to encounter numerous issues, including misfolding, tonic signaling, immunogenicity, and the difficulty in identifying certain tumor epitopes. Nanobody-based CARs employing VHHs constitute a compact, small, and highly selective alternative for tumor targeting. This review analyzes the molecular architecture, functional advantages, and clinical utilizations of nanobody CAR-T cells. We describe the structural features, including solubility, chemical resistance, and modularity that facilitate the advanced development of bispecific, trivalent, and logic-gated CAR forms. Preclinical studies demonstrate significant cytotoxicity of cells in vitro, elevated cytokine release, and successful in vivo tumor regression in both hematologic malignancies and solid tumors. Early-phase clinical trials, particularly targeting approaches based on BCMA (B cell maturation antigen), have presented encouraging safety profiles, persistence, and antitumor activity. Although there has been so much advancement, there are several limitations, such as the challenge of tumor heterogeneity, immune evasion, and T cell exhaustion. Innovative approaches, such as off-the-shelf allogeneic CARs, armored CARs, combination therapy based on checkpoint blockade or vaccines, and synthetic biology circuits, have the capabilities for overcoming several challenges listed above. Overall, nanobody CAR-T cells represent a flexible and innovative platform, which has a likelihood of increasing specificity, safety, and accessibility, thus paving the way for their wider integration in precision oncology beyond hematologic cancers.
Key Findings
1
Early clinical trials, especially BCMA-targeted approaches, indicate encouraging safety, CAR-T persistence, and antitumor activity.
2
Nanobody-based CAR-T cells use compact VHH domains to improve tumor-targeting selectivity while addressing ScFv-associated misfolding, tonic signaling, immunogenicity, and epitope-access limitations.
3
Preclinical studies report strong in vitro cytotoxicity, increased cytokine release, and in vivo tumor regression across hematologic malignancies and solid tumors.
4
Tumor heterogeneity, immune evasion, and T-cell exhaustion remain major barriers; proposed solutions include allogeneic off-the-shelf, armored, combination, and synthetic-biology CAR strategies.
5
VHH structural properties—including solubility, chemical resistance, and modularity—support development of bispecific, trivalent, and logic-gated CAR architectures.
Research Object
nanobody-based CAR-T cells employing VHH single-domain antibodies for tumor targeting
Research Subject
the molecular design, structural and functional advantages, clinical translation, safety, persistence, antitumor activity, and limitations of nanobody-based CAR-T therapy
Publication Details
Publication Date
2025-11-29
Journal
Publisher
ISSN
Cited by
9
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest